Trials / Completed
CompletedNCT02425748
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
γδ T Cell Immunotherapy for Treatment of
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
Detailed description
Non small lung cancer will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DC-CIK | DC-CIK cells will be used against tumor cells. |
| BIOLOGICAL | γδ T Cell | γδ T cells will be used against non small lung tumor. |
| BIOLOGICAL | γδ T/DC-CIK cells | γδ T/DC-CIK cells will be used against lung tumor. |
Timeline
- Start date
- 2017-06-08
- Primary completion
- 2017-12-20
- Completion
- 2019-06-20
- First posted
- 2015-04-24
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02425748. Inclusion in this directory is not an endorsement.